**COMET: K-Project**

**BioPersMed**

**Biomarker for personalised medicine in common metabolic disorders**

<table>
<thead>
<tr>
<th>Main location</th>
<th>Medical University of Graz</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other locations</td>
<td>-</td>
</tr>
<tr>
<td>Research programme</td>
<td>Endokrinology</td>
</tr>
<tr>
<td></td>
<td>Hepatologie</td>
</tr>
<tr>
<td></td>
<td>Vaskular Cardiology</td>
</tr>
</tbody>
</table>

**Planned realisation and outcomes**

The aim of BioPersMed is the development of diagnostic methods based on biomarkers for common metabolic disorders, in order to improve prognosis concerning the individual course of disease. Thus prevention and therapy will earlier be possible, the healing potential will increase and thus quality of human life will considerably be improved. This will especially result in a positive effect on the health care system in general, as expensive therapy failures can be avoided.

**History of establishment**

Based on the substantial core competencies of the Med Uni Graz in the field of metabolic disorders and the largest clinical European biobank located also here, the project BioPersMed has been initiated. There has already existed good cooperation with the scientific partners and some of the company partners that should be refined via bundling of resources in BioPersMed. To make it perfect, further company partners have been included in the consortium and BioPersMed has been designed.

**Selected company partners** (max. 10)

1. Bayer Schering Pharma AG
2. BIOCRATES Lifesciences AG
3. BIOMARKER DESIGN Forschungs GmbH
4. IASON GmbH
5. IDS Immunodiagnostic Systems Deutschland GmbH
6. JSW Lifesciences GmbH
7. Noxygen Science Transfer & Diagnostics GmbH
8. Protagen AG
9. Siemens Healthcare Diagnostics GmbH
10. SustSol GmbH

**Selected scientific partners** (max. 5)

1. Joanneum Research Forschungsgesellschaft mbH, Institute of Medical Technologies and Health Management
2. Ludwig Boltzmann Gesellschaft, Ludwig Boltzmann Institut für experimentelle und klinische Traumatologie
3. Medical University of Vienna

**Selected international partners** (max. 5)

1. Bayer Schering Pharma AG
2. BioVendor Laboratoriums medicina a.s.
3. IDS Immunodiagnostic Systems Deutschland GmbH
4. Noxygen Science Transfer & Diagnostics GmbH
5. Protagen AG

**Start Date**

01/07/2010

**Planned number of personnel**

87,48 (FTE) thereof researcher 58,31

**Total costs**

EUR 6,8 Mio

**Leader of consortium:**

Medical University of Graz, Dr. Karine Sargsyan

**Contact:**

Universitaetsplatz 3, A-8010 Graz
karine.sargsyan@medunigraz.at
http://www.medunigraz.at/biopersmed

---

1 Partners with headquarters outside Austria
2 First funding period: K1-Centres: 4 years, K2-Centers: 5 years;